Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > SEMAGLUTIDE LONG-ACTING INJECTION (SYH9017) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

SEMAGLUTIDE LONG-ACTING INJECTION (SYH9017) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

June 08, 2026

a260608a_00.png

Next: VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL STUDY DATA OF NOVEL B7-H3 ANTIBODY-DRUG CONJUGATE SYS6043 PRESENTED IN AN ORAL SESSION AT THE 2026 ASCO ANNUAL MEETING

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC PHARMACEUTICAL GROUP LIMITED All Rights Reserved | 冀ICP备05003393号

Wechat